ESC/EACTS recommends adjusting PCI for left main CAD in low surgical risk patients
Italy: A European task force comprised of cardiologists, interventionalists, and cardiac surgeons from the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) is proposing changes to the guidelines for percutaneous coronary intervention (PCI) in patients with left main coronary artery disease (CAD) as published in European Heart Journal by Robert A Byrne and colleagues. The task force suggests that PCI for stable patients with left main CAD and a low or intermediate SYNTAX score (0-32) should be classified as a class IIa (level of evidence A) recommendation, rather than the current class I recommendation for those with a low SYNTAX score (0-22).
Key points from the task force's recommendations:
Adjustment in PCI Recommendation: The task force proposes that PCI for low surgical risk patients with left main CAD and a low or intermediate SYNTAX score should be considered a class IIa recommendation. This change aligns with PCI recommendations for low and intermediate SYNTAX scores.
The controversy over the optimal approach to treat patients with left main CAD emerged several years ago, fueled by concerns over all-cause mortality rates associated with PCI. The ESC formally requested an independent review of published trials, which concluded there was no significant difference in death rates between PCI and surgery at 5 years.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.